Evidence map›Paper›PMID 29959561›Full record

ArticleApoptosis : an international journal on programmed cell death2018

P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Zhongyan Hua, Yue Zhan, Simeng Zhang, Yudi Dong, Min Jiang, Fei Tan, Zhihui Liu, Carol J Thiele, Zhijie Li

Abstract read
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. BDNF Therapeutic Mechanisms in Neuropsychiatric Disorders.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Zhongyan HuaMedical Research Center, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, China.
Yue ZhanMedical Research Center, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, China.
Simeng ZhangMedical Research Center, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, China.
Yudi DongMedical Research Center, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, China.
Min JiangMedical Research Center, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, China.
Fei TanDepartment of Neurology, Shengjing Hospital of China Medical University, Shenyang, China.
Zhihui LiuCellular & Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Carol J ThieleCellular & Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Zhijie LiMedical Research Center, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, China. lizhijie68@hotmail.com.
China Medical University · CNNational Cancer Institute · USNational Institutes of Health · US

Funding

Regulation of Differentiation of Pediatric Embryonal Tumors- NeuroblastomaZIABC010788 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI THIELE, CAROL J · 2009 to 2025
$29.7M
Pathophysiologic Consequences of Survival Signaling in NeuroblastomaZIABC010789 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI THIELE, CAROL J · 2009 to 2023
$12.0M
Pathophysiologic Consequences of Neurotrophin Activation of Trk in NeuroblastomaZ01BC010789 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI THIELE, CAROL J · 2007 to 2008
$1.1M
Intramural NIH HHS Z01 BC010789
6 · The paper itself

Abstract

The over-expressions of brain-derived neurotrophic factor (BDNF) and its tyrosine kinase receptor TrkB have been reported to induce chemo-resistance in neuroblastoma (NB) cells. In this study, we investigated the roles of P53 and BCL2 family members in the protection of BDNF/TrkB from etoposide-induced NB cell death. TB3 and TB8, two tetracycline (TET)-regulated TrkB-expressing NB cell lines, were utilized. The expressions of P53 and BCL2 family members were detected by Western blot or RT-PCR. Transfection of siRNAs was used to knockdown P53 or PUMA. Activated lentiviral was used to over-express PUMA. Cell survival was performed by MTS assay, and the percentage of cell confluence was measured by IncuCyte ZOOM. Our results showed that etoposide treatment induced significant and time-dependent increase of P53, which could be blocked by pre-treatment with BDNF, and knockdown P53 by transfecting siRNA attenuated etoposide-induced TrkB-expressing NB cell death. PUMA was the most significantly changed BCL2 family member after treatment with etoposide, and pre-treatment with BDNF blocked the increased expression of PUMA. Transfection with siRNA inhibited etoposide-induced increased expression of PUMA, and attenuated etoposide-induced NB cell death. We also found that over-expression of PUMA by infection of activated lentiviral induced TrkB-expressing NB cell death in the absence of etoposide, and treatment of BDNF protected NB cells from PUMA-induced cell death. Our results suggested that P53 and PUMA may be potential targets that mediated the protection of BDNF/TrkB from etoposide-induced NB cell death.

Indexed as

ApoptosisApoptosis Regulatory ProteinsBrain-Derived Neurotrophic FactorCell DeathCell Line, TumorCell SurvivalCisplatinDrug Resistance, NeoplasmEtoposideHumansNeuroblastomaTumor Suppressor Protein p53Apoptosis Regulatory ProteinsBrain-Derived Neurotrophic FactorCisplatinEtoposideTumor Suppressor Protein p53BDNFEtoposideNeuroblastomaP53PUMATrkB

Identifiers

PMID29959561
PMCPMC6294298
OpenAlexW2810851724

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.